FDA promoting master protocols, adaptive trials

Draft guidance documents FDA released Friday on master protocols for oncology drugs and adaptive clinical trial designs are intended to streamline clinical trial development while providing higher quality data to physicians, patients and regulators than conventional approaches.

The guidance documents will “facilitate innovative trial designs that can make trials not only more efficient and less costly, but also more rigorous,” FDA Commissioner Scott Gottlieb said Friday in a speech at the University of Pennsylvania. ...